Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
Status:
Recruiting
Trial end date:
2022-11-05
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is to evaluate the long-term safety of glepaglutide
treatment in patients with short bowel syndrome (SBS).
Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.